pp32 reduction induces differentiation of TSU-Pr1 cells.

[1]  A. Shevchenko,et al.  Analysis of the Adenovirus E1B-55K-Anchored Proteome Reveals Its Link to Ubiquitination Machinery , 2002, Journal of Virology.

[2]  D. Bostwick,et al.  Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival. , 2002, The Journal of urology.

[3]  M. Szyf,et al.  The Oncoprotein Set/TAF-1β, an Inhibitor of Histone Acetyltransferase, Inhibits Active Demethylation of DNA, Integrating DNA Methylation and Transcriptional Silencing* , 2002, The Journal of Biological Chemistry.

[4]  P. McNamara,et al.  Regulation of Histone Acetylation and Transcription by Nuclear Protein pp32, a Subunit of the INHAT Complex* , 2002, The Journal of Biological Chemistry.

[5]  N. Rosen,et al.  The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. , 2001, Cancer research.

[6]  P. Marks,et al.  Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.

[7]  S. Parsons,et al.  Interleukin-6- and Cyclic AMP-Mediated Signaling Potentiates Neuroendocrine Differentiation of LNCaP Prostate Tumor Cells , 2001, Molecular and Cellular Biology.

[8]  P. Pandolfi,et al.  Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. , 2001, The Journal of clinical investigation.

[9]  C. Korch,et al.  TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin. , 2001, Cancer research.

[10]  H. Yost,et al.  Protein phosphatase 2A and its B56 regulatory subunit inhibit Wnt signaling in Xenopus , 2001, The EMBO journal.

[11]  Gary R Pasternack,et al.  Tumor suppression and potentiation by manipulation of pp32 expression , 2001, Oncogene.

[12]  N. Yamamoto,et al.  Upregulation of p21WAF1/CIP1 leads to morphologic changes and esterase activity in TPA-mediated differentiation of human prostate cancer cell line TSU-Pr1 , 2001, Oncogene.

[13]  L. Nabors,et al.  HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3' untranslated regions of cytokine and angiogenic factor mRNAs. , 2001, Cancer research.

[14]  P. McNamara,et al.  Regulation of Histone Acetylation and Transcription by INHAT, a Human Cellular Complex Containing the Set Oncoprotein , 2001, Cell.

[15]  J. Steitz,et al.  Protein Ligands to Hur Modulate Its Interaction with Target Mrnas in Vivo , 2000, The Journal of cell biology.

[16]  R A Rifkind,et al.  Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. , 2000, Cancer research.

[17]  K. Takeda,et al.  Low‐Dose staurosporine suppresses proliferation and induces neurites in human prostatic cancer TSU‐Pr1 cells , 2000, The Prostate.

[18]  S. Lakhani,et al.  Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. , 1999, Cancer research.

[19]  J. Rebel,et al.  Identification of Sequences Required for Inhibition of Oncogene-mediated Transformation by pp32* , 1999, The Journal of Biological Chemistry.

[20]  B. Bonavida,et al.  Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. , 1999, Biochemical and biophysical research communications.

[21]  Raymond L. White,et al.  Regulation of β-Catenin Signaling by the B56 Subunit of Protein Phosphatase 2A , 1999 .

[22]  D. S. Coffey,et al.  Stem cell features of benign and malignant prostate epithelial cells. , 1998, The Journal of urology.

[23]  B. Ballermann,et al.  Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms' tumor. , 1998, Journal of the American Society of Nephrology : JASN.

[24]  G. Pasternack,et al.  Novel nuclear phosphoprotein pp32 is highly expressed in intermediate‐ and high‐grade prostate cancer , 1998, The Prostate.

[25]  F. Mitelman,et al.  Expression analysis and chromosomal mapping of a novel human gene, APRIL, encoding an acidic protein rich in leucines. , 1998, Biochimica et biophysica acta.

[26]  Z. Damuni,et al.  Molecular identification of I1PP2A, a novel potent heat-stable inhibitor protein of protein phosphatase 2A. , 1996, Biochemistry.

[27]  D. S. Coffey,et al.  A novel M(r) 32,000 nuclear phosphoprotein is selectively expressed in cells competent for self-renewal. , 1993, Cancer research.

[28]  P. Carroll,et al.  Cell proliferation in prostatic adenocarcinoma: in vitro measurement by 5-bromodeoxyuridine incorporation and proliferating cell nuclear antigen expression. , 1993, The Journal of urology.

[29]  W. Isaacs,et al.  ras gene mutations in human prostate cancer. , 1990, Cancer research.

[30]  H. Bonkhoff.  Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  R. Moon,et al.  Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A. , 1999, Science.